Oncology
Digestive System Neoplasm
11
Pipeline Programs↗
3
Active Trials↗
4
Companies Involved↗
Digestive System Neoplasm is an emerging landscape with 11 programs across 4 companies. The most active players are McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Hengrui Therapeutics, Inc., BeiGene. 1 therapy is approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 16
Phase 3
No programs
Approved1
Analysis
Modality Breakdown
9programs
Small molecule556%
Monoclonal antibody222%
Cell therapy111%
Vaccine111%
Modality classified for 100% of 11 pipeline programs.
Analysis
Trial Status
6
clinical trials
Unknown status3 · 50%
Recruiting3 · 50%
Clinical Trials
Trial Activity
6 trials
Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms
Unknown status·BBeijing Immunochina Medical Science & Technology Co., Ltd.·Phase 1·NCT05287165·19 enrolled
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms
Unknown status·—·N/A·NCT03468244·24 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)